Advertisement

 

 

Thyroid dysfunctions secondary to cancer immunotherapy.

Thyroid dysfunctions secondary to cancer immunotherapy.
Author Information (click to view)

Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P,


Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P, (click to view)

Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of endocrinological investigation 2017 12 13() doi 10.1007/s40618-017-0778-8

Abstract
BACKGROUND
Immunotherapy is a firmly established pillar in the treatment of cancer, alongside the traditional approaches of surgery, radiotherapy, and chemotherapy. Like every treatment, also cancer immunotherapy causes a diverse spectrum of side effects, collectively referred to as immune-related adverse events.

OBJECTIVE
This review will examine the main forms of immunotherapy, the proposed mechanism(s) of action, and the incidence of thyroid dysfunctions.

METHODS
A comprehensive MEDLINE search was performed for articles published up to March 30, 2017.

RESULTS
Following the pioneering efforts with administration of cytokines such as IL-2 and IFN-g, which caused a broad spectrum of thyroid dysfunctions (ranging in incidence from 1 to 50%), current cancer immunotherapy strategies comprise immune checkpoint inhibitors, oncolytic viruses, adoptive T-cell transfer, and cancer vaccines. Oncolytic viruses, adoptive T-cell transfer, and cancer vaccines cause thyroid dysfunctions only rarely. In contrast, immune checkpoint blockers (such as anti-CTLA-4, anti-PD-1, anti-PD-L1) are associated with a high risk of thyroid autoimmunity. This risk is highest for anti-PD-1 and increases further when a combination of checkpoint inhibitors is used.

CONCLUSIONS
Cancer patients treated with monoclonal antibodies that block immune checkpoint inhibitors are at risk of developing thyroid dysfunctions. Their thyroid status should be assessed at baseline and periodically after initiation of the immunotherapy.

Submit a Comment

Your email address will not be published. Required fields are marked *

four × four =

[ HIDE/SHOW ]